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nitroprusside, SNP) for internal infections would present significant toxicity risks due to 126 systemic exposure of the host to NO [10] ; and (c) developing NO-donor/antibiotic 127 combinations is difficult due to divergent pharmacokinetics and other drug properties of the 128 two molecules. In addition, the lack of specificity towards bacteria and its short half-life 129 make NO treatment of biofilm infections challenging [6] . To address these issues, we are 130 investigating cephalosporin-3´-diazeniumdiolates (C3Ds) as novel, biofilm-activated NO-131 donor prodrugs. 132
C3Ds contain a stabilized diazeniumdiolate NO-donor (NONOate) attached at the 3'-133 position of early generation cephalosporins and were designed to selectively deliver NO to 134 biofilm infection sites following β-lactam ring cleavage mediated by bacterial β-lactamases. 135
It was envisaged that the compounds could be used as targeted NO carriers in combination 136 with conventional antibiotics to treat chronic, β-lactamase expressing, biofilm infections 137 infections (e.g. sinusitis and otitis media). Despite introduction of pneumococcal conjugate 157 vaccines, the clinical incidence of pneumococcal otitis media has stayed largely unchanged 158 due to serotype replacement, and otitis media remains a primary cause of antibiotic 159 prescription in children [14; 15; 16; 17; 18] . S. pneumoniae is also a non-β-lactamase-160 producing organism that uses transpeptidases/PBPs in the construction of its cell wall [19] . with stirring in a septum-sealed acrylic chamber and baseline NO levels were monitored over 222 5 min. PYRRO-C3D (100 µM) was then added and the NO signal recorded for 5 min before 223 adding 10 units of Bacillus cereus penicillinase (Sigma; P0389) and monitoring NO levels for 224 a further 120 min. To measure release of NO from PYRRO-C3D in the presence of 225 pneumococcal cells, the ISO-NO probe was submerged into the media and positioned directly 226 above 48 h serotype 14 biofilms (grown as described above). NO concentrations were 227 monitored over the ensuing 10 minutes to confirm no endogenous NO production, before 228 adding 100 µM PYRRO-C3D and recording the NO signal for a further 40 minutes. 229 230
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Confocal Laser Scanning Microscopy (CLSM). 231
Mid-exponential planktonic cultures of serotype 2 strain D39 (containing the plasmid 232 pMV158GFP) were grown in BHI and used to inoculate 35 mm untreated glass bottom 233 NO release from PYRRO-C3D was examined first in the presence of a β-lactamase 254 (penicillinase) using the NO probe. PYRRO-C3D (100 µM) showed low-level release of NO 255 over 5 minutes after being added to HBSS (pH 7.4) at 37 ˚C. Subsequent addition of 10 units 256 of penicillinase caused a rapid spike of NO, reaching a peak concentration of 450 nM within 257 5 min, which was followed by a steady decline over 2 h, confirming that PYRRO-C3D 258 efficiently releases NO following β-lactam ring cleavage (Figure 2a) . pneumococcal viability by CFU enumeration showed a concentration-dependent response to 300 PYRRO-C3D, culminating in a 3-log reduction in biofilm CFUs at 100 µM (p=0.014) (Figure  301 3b). As seen in the planktonic phenotype, cephaloram showed identical activity to PYRRO-302 C3D (3-log reduction in biofilm CFUs at 100 µM, p=0.029) and DEA/NO showed no effect 303 below 100 µM (p=0.49). A 4-log reduction was also observed in CFUs grown from the 304 supernatant surrounding PYRRO-C3D (100 µM) treated cells, compared to untreated controls 305 with DEA/NO showed no effect on biofilm viability, whereas a significant reduction in 315 biofilm viability was observed following PYRRO-C3D treatment (Figure 4c, -e) . Established 48 h D39 biofilms expressing GFP were treated with 100 µM PYRRO-C3D or 320 DEA/NO for 2 hours and imaged using confocal microscopy. Biofilms were counterstained 321 with propidium iodide to distinguish dead cells from GFP-expressing viable cells (green). 322
Treatment with DEA/NO and PYRRO-C3D had no effect on either a) maximum biofilm 323 height, or b) biofilm biomass compared to untreated controls. Treatment with PYRRO-C3D, 324
and not DEA/NO, reduced the number of viable bacteria present within the biofilm (c-e). 325 326
Activity of PYRRO-C3D against pneumococcal biofilms is exclusively mediated 327 through the cephalosporin β-lactam. 328
Having established that 100 µM PYRRO-C3D was effective in reducing 329 pneumococcal viability in biofilms (Figure 3) , the treatment was repeated in the presence of 330 the β-lactamase inhibitor clavulanic acid (250 g.mL -1 ) . No change in the response to 331 PYRRO-C3D was observed (p=0.929) (Fig. 5a ), confirming that β-lactamases were playing 332 next repeated in the presence of the NO-scavenger cPTIO. Addition of 50 µM cPTIO, which 334 showed no effect on its own, did not change the activity of PYRRO-C3D (p=0.829, Fig. 5b) , 335 confirming that the NO being released from PYRRO-C3D was having no effect. The effect of 336 PYRRO-C3D on S. pneumoniae viability was then assessed in the presence of 0.01 U/µL 337 penicillinase, the same β-lactamase shown to cleave the β-lactam of PYRRO-C3D and 338 liberate NO (Figure 2) . Addition of penicillinase significantly reduced the activity of 339 PYRRO-C3D (p=0.0286, Fig. 5c ). Together these data provide compelling evidence that 340 PYRRO-C3D produces direct activity against biofilm pneumococci via reaction of its 341 cephalosporin β-lactam with transpeptidases/PBPs only, and that subsequent release of NO 342 from the compound produces no measurable effect on cell viability. µM PYRRO-C3D, 300 µg/mL amoxicillin or 1 mg/mL azithromycin for 2 hours and assessed 368 for pneumococcal viability by CFU enumeration. *p≤0.05; ***p≤0.001. 369 370
Discussion 371
Previous studies showed that low levels of NO were released from our prototype C3D 372 (DEA-CP) in the presence of non-β-lactamase producing E. coli cell extracts [11] and it was 373 postulated that the NO release resulted from reaction of the compound with PBPs, the 374 enzymes responsible for cross-linking peptidoglycan chains during bacterial cell wall 375 synthesis. It is well known that cephalosporins and other β-lactam antibiotics elicit 376 antibacterial effects by covalently binding to the active sites of PBPs in a process that also 377 results in β-lactam ring cleavage [24] . This led us to speculate that reactions between PBPs 378
and C3Ds might elicit a direct, β-lactam-mediated antibacterial effect and in the process 379 liberate the NONOate (and NO) (Fig. 1) . Since anti-biofilm effects of NO are now well 380 documented, we postulated that NO released from C3Ds following reaction with PBPs might 381 confer additional anti-biofilm activity. 382
We tested this dual-activity hypothesis using non-β-lactamase producing S. 383 pneumoniae strains that express five high molecular weight PBPs (1a, 1b, 2a, 2b and 2x) and 384 one low molecular weight PBP3 [19] . The absence of β-lactamases ensured that NO released 385 from the compound must arise from an alternative mechanism, most likely PBP-mediated β-386 lactam cleavage. The representative C3D selected for the study was PYRRO-C3D, a close 387 structural analogue of DEA-CP that carries PYRRO/NO (t 1/2 = 2 secs) as the NONOate 388 instead of DEA/NO (t 1/2 = 2 min) [25] . PYRRO-C3D was chosen for its faster NO release, 389 which we believe would be important for C3D use in vivo since diffusion of an expelled 390
NONOate away from infection sites (before releasing the NO cargo) would reduce 391 effectiveness and raise NO-mediated safety concerns. Finally, the antibacterial activity of PYRRO-C3D towards pneumococcal biofilms 420 was compared with that of antibiotics commonly used to treat pneumococcal infections. We 421 found that PYRRO-C3D possessed similar antibacterial efficacy to amoxicillin against both 422 serotype 2 and 14 biofilms, which is perhaps not surprising given that the compounds are 423 structurally and functionally very similar, with both targeting PBP-mediated cell wall 424 synthesis. PYRRO-C3D was found to be much more effective than azithromycin, an 425 antibiotic that targets protein biosynthesis. 426
The findings presented here are consistent with our recent study, which showed that 427 
